The FAS initiated a case against "Nizhpharm" due to the price increase of "Edarbi."

      May 19, 2026 18:18 Economy The Federal Antimonopoly Service has initiated a case against the pharmaceutical company "Nizhpharm" due to the cost of the drug "Edarbi." The reason for the inspection was a citizen's appeal to the FAS. During the investigation, the service established that the drug is not included in the list of essential and vital medicines, therefore state price regulation does not apply to it. At the same time, the antimonopoly agency noted that "Nizhpharm" is the only manufacturer of this drug in Russia, and there are no analogs available. According to the FAS, the company raised the price of "Edarbi" by 19-28% without sufficient grounds. The service indicated that as the production cost of the drug decreased, the profit growth rates significantly exceeded the increase in production costs. If the company's guilt is proven, "Nizhpharm" may face a fine or the transfer of illegally obtained income to the budget. Earlier, the NIA "Nizhny Novgorod" editorial team found out why immunoglobulin for pregnant women is absent in Nizhny Novgorod pharmacies. NIA "Nizhny Novgorod" has channels on Telegram and MAX. Subscribe to stay updated on the main events, exclusive materials, and operational information. Copyright © 1999—2025 NIA "Nizhny Novgorod". When reprinting, a hyperlink to NIA "Nizhny Novgorod" is mandatory. This resource may contain materials 18+